SuperworthNeogen EPS NEOG
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Aug 31, 2026
- −$0.25
- Latest quarter, Q1 FY27
- −$0.05
- −129% on a year earlier
- Fiscal year 2026
- −$0.03
Neogen's earnings per share was −$0.25 over the twelve months to Aug 31, 2026.
In its latest quarter, Q1 FY27, it was −$0.05, down 129% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2026 | −$0.03 | n/a |
| FY2025 | −$5.03 | n/a |
| FY2024 | −$0.04 | n/a |
| FY2023 | −$0.07 | −116% |
| FY2022 | $0.45 | −21% |
| FY2021 | $0.57 | +1% |
| FY2020 | $0.56 | −2% |
| FY2019 | $0.57 | −5% |
| FY2018 | $0.60 | +32% |
| FY2017 | $0.46 | −5% |
| FY2016 | $0.48 | +8% |
| FY2015 | $0.45 | +18% |
| FY2014 | $0.38 | +1% |
| FY2013 | $0.38 | +20% |
| FY2012 | $0.31 | −3% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q1 FY27 | −$0.05 | −129% | −$0.25 | |
| Q4 FY26 | −$0.05 | n/a | −$0.03 | |
| Q3 FY26 | −$0.08 | n/a | −$2.80 | |
| Q2 FY26 | −$0.07 | n/a | −$2.77 | |
| Q1 FY26 | $0.17 | n/a | −$4.80 | |
| Q4 FY25 | −$2.82 | n/a | −$5.03 | |
| Q3 FY25 | −$0.05 | n/a | −$2.23 | |
| Q2 FY25 | −$2.10 | n/a | −$2.19 | |
| Q1 FY25 | −$0.06 | −700% | −$0.11 | |
| Q4 FY24 | −$0.02 | −167% | −$0.04 | |
| Q3 FY24 | −$0.01 | −125% | $0.01 | |
| Q2 FY24 | −$0.02 | n/a | $0.06 |
Against its peers
Companies in Medical - Diagnostics & Research nearest Neogen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NEOGNeogen | −$0.25 | |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| BLLNBillionToOne | $0.65 | |
| LNTHLantheus | $4.13 | +10% a year |
| CAICaris Life Sciences | $0.37 | |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| NRCNRC Health | $0.25 | −67% a year |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Neogen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.